Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyang Pharma Univ. Mcl-1 compound 26
- Development stage
- Unknown
- Lead developer
- Shenyang Pharmaceutical University
01
Overview
Shenyang Pharma Univ. Mcl-1 compound 26: sourced facts only. name: "Among those compounds, 26 exerted relatively better affinity and selectivity for Mcl-1 with moderate inhibition in HL-60 cells." [PMID:35901526]; target: "Among those compounds, 26 exerted relatively better affinity and selectivity for Mcl-1 with moderate inhibition in HL-60 cells." [PMID:35901526]; developer: "Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:35901526]
02
Targets
MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on Shenyang Pharma Univ. Mcl-1 compound 26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Pharma Univ. Mcl-1 compound 26.